BiotechPark with Innovation- and Incubationscenter
Berlin-Buch, with its long tradition of excellent biomedical basic and clinical research as well as clinical expertise, is an ideal environment for life science companies. The campus atmosphere is conducive to scientific exchange, technology transfer and collaborative projects.
With an area of approximately 45,000 m², the BiotechPark Berlin-Buch is one of the largest biotech parks in Germany. Here entrepreneurs and companies find affordable, industry-specific laboratory and office space with state-of-the-art facilities. Start-ups can grow and thrive in the Innovation and Incubation Center, building areas on the Campus allow for future development. The managing company, Campus Berlin-Buch GmbH, supports the companies in all matters and provides comprehensive service.
Currently, 75 companies are located on campus and employ around 850 people. More than fifty of these companies are in the biotech sector, several others offer services for the life science industry. Since 1998 the number of employees of the biotech companies has more than doubled.
The business fields of the companies range from medical technology products, molecular biological diagnostics and treatments, preclinical pharmacological and pharmacogenomic tests, RNA technologies, the search for pharma-relevant target molecules, production and testing of drugs and the analysis and synthesis of biomolecules.
Since 2023 the new BerlinBioCube start-up center in BiotechPark Berlin-Buch offers an additional 8,000 square meters of laboratory and office space and attractive services for start-ups in the fields of biotechnology and medical technology as well as adjacent areas.
„Made in Buch“ stands for high quality and innovation in the life sciences. Selected products can be found here.
News innovation
Pentixapharm publishes positive Phase II data on Pentixafor PET diagnostics
The study confirms PENTIXAFOR-PET as a non-invasive alternative to adrenal vein catheterization in primary aldosteronism
more ...Eckert & Ziegler on Track as Planned and Achieves Another Record Year in 2025
According to preliminary, unaudited figures for the 2025 financial year, Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) generated sales of around € 312 million and adjusted EBIT of around € 78 millio...
more ...A fresh take on proteomics
Start-up company Absea Biotechnology GmbH is developing new proteomics technologies. An interview with Dr. Philip Lössl, Senior VP Science and Business Development
more ...Events Campus
25.02.2026, 10:00
JUGEND FORSCHT – 61. Regional-Wettbewerb: Maximale Perspektive
Für die 61. Wettbewerbsrunde von Jugend forscht haben sich mehr als 11 000 Jungforscherinnen und Jungforscher angemeldet - die Beteiligung ist deutlich gestiegen.
more ...18.03.2026, 08:30
vocatium Berlin focus 2026: Fachmesse für Ausbildung+Studium
Entdecke berufliche Möglichkeiten, informiere dich und sprich mit Expert:innen über Einstieg, Voraussetzungen und Bewerbung.
more ...20.03.2026, 08:45
Einladung: UniStem Day für Berliner Schülerinnen und Schüler aus Biokursen
Das German Stem Cell Network (GSCN) lädt die an Biologie interessierten Berliner Schülerinnen und Schüler (Biologie-Leistungskurse und Grundkurse) mit ihren Lehrkräften herzlich zum UniStem Day – zum ...
more ...